Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension

Author's Avatar
Jan 07, 2019
Article's Main Image

- These initial data show the potential for the vast majority of patients to remain treatment free for at least 1 year -

- Allergan plans US NDA submission in second half of 2019 -

PR Newswire